Standard BioTools Posts Q4 Revenue of $23.8M, Activates $40M Savings, Holds $550M Cash
Standard BioTools reported Q4 2025 revenue of $23.8 million and full-year revenue of $85.3 million with Q4 net income of $13.9 million. The company has activated over $40 million in cost savings, holds about $550 million in cash post-SomaLogic sale, targeting positive adjusted EBITDA and cash flow by end-2026.
1. Q4 and Full-Year 2025 Financial Results
Standard BioTools reported revenue from continuing operations of $23.8 million in the fourth quarter of 2025, a 4% year-over-year decline, and full-year revenue of $85.3 million. The company achieved a non-GAAP gross margin of 50.3% in Q4 and 53.6% for the full year, reversing to a Q4 net income of $13.9 million from a $27.2 million loss in the year-ago quarter.
2. Cost Savings and Operating Expenses
In Q4 2025, operating expenses were $36.0 million, down 4% year-over-year, with non-GAAP operating expenses of $27.8 million, a 1% reduction. Standard BioTools has fully operationalized over $40 million in annualized cost savings initiatives to support its path to positive adjusted EBITDA.
3. Balance Sheet Strength
Following the January 30, 2026 closing of the SomaLogic divestiture, the company holds approximately $550 million in cash and liquid investments. This strong liquidity position, combined with roughly $1 billion in net operating loss carryforwards, provides significant flexibility to pursue disciplined inorganic growth opportunities.
4. Outlook and Profitability Targets
Standard BioTools is targeting positive adjusted EBITDA and adjusted cash flow exiting 2026, driven by disciplined execution of the Standard BioTools Business System, ongoing efficiency measures, and potential M&A investments funded by its robust balance sheet.